Sign up USA
Proactive Investors - Run By Investors For Investors

Resapp Health to restart respiratory app study after enhancing its technology

Doctors Without Borders is not proceeding with its evaluation of the app.
A woman coughing
An improved audio recording app will now be deployed

Resapp Health Ltd (ASX:RAP) is planning to restart the U.S. paediatric clinical study of its “ResAppDx” app to detect respiratory diseases, this U.S. winter.

The company’s smartphone app works by using algorithms to analyse the sound of a patient’s cough and provide a diagnosis.

To improve the data-gathering element of the study, ResApp will now be regularly present onsite conducting clinical study team training, reviewing enrolment procedures and verifying data.

This is to help ensure that high-quality cough sounds are collected as early as possible during the patient’s hospital visit and prior to any treatment known to affect cough analysis.

Furthermore, an improved audio recording smartphone application incorporating built-in checklists, automated background noise estimation and additional visual aids will be deployed.

This is to support the data collection teams and eliminate inappropriate collection of cough data with background noise contamination.

However, Doctors Without Borders is not proceeding with its evaluation of ResAppDx, following the review of the issues identified in Resapp’s earlier study and the high cost of keeping the project open.

ResApp and Doctors Without Borders will maintain their collaborative relationship and seek opportunities for field testing the technology once the issues have been resolved.

All sites have reaffirmed their intention to rerun the updated study and are targeting to restart the study before the beginning of the U.S. winter season.

View full RAP profile View Profile

ResApp Health Ltd Timeline

Newswire
April 18 2016

Related Articles

biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies
picture of drug research
August 22 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use